| __timestamp | Neurocrine Biosciences, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 13774000 |
| Thursday, January 1, 2015 | 32480000 | 22479000 |
| Friday, January 1, 2016 | 68081000 | 27388000 |
| Sunday, January 1, 2017 | 169906000 | 35610000 |
| Monday, January 1, 2018 | 248932000 | 49007000 |
| Tuesday, January 1, 2019 | 354100000 | 61139000 |
| Wednesday, January 1, 2020 | 433300000 | 68836000 |
| Friday, January 1, 2021 | 583300000 | 97592000 |
| Saturday, January 1, 2022 | 752700000 | 106903000 |
| Sunday, January 1, 2023 | 887600000 | 120998000 |
| Monday, January 1, 2024 | 1007200000 |
Unlocking the unknown
In the competitive landscape of biotechnology, understanding spending patterns is crucial. Over the past decade, Neurocrine Biosciences, Inc. and Vericel Corporation have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Neurocrine's SG&A expenses have surged by nearly 4,800% from 2014 to 2023, reflecting its aggressive growth strategy and market expansion. In contrast, Vericel's expenses have increased by approximately 780% over the same period, indicating a more measured approach.
By 2023, Neurocrine's SG&A expenses reached nearly nine times that of Vericel, highlighting its significant investment in administrative and sales capabilities. This divergence in spending underscores the different strategic priorities of these companies. As the biotech sector continues to evolve, monitoring these financial patterns offers valuable insights into corporate strategies and market positioning.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Amgen Inc. vs Vericel Corporation: SG&A Expense Trends
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Vericel Corporation
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Vericel Corporation
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Vericel Corporation
Cost Management Insights: SG&A Expenses for Vericel Corporation and HUTCHMED (China) Limited